China Insulin Industry Report, 2012-2015
  • Jan.2013
  • Hard Copy
  • USD $1,900
  • Pages:70
  • Single User License
    (PDF Unprintable)       
  • USD $1,800
  • Code: CYH007
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,800
  • Hard Copy + Single User License
  • USD $2,100

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant human insulin and insulin analog accounted for 52.8%.

Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so.

Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a major supplier in China’s insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011.

America-based Eli Lilly and Company is the second embarking on Chinese insulin market, with the recombinant human insulin market share of 17% and the insulin analog market share of 8% in 2011. Moreover, Eli Lilly and Company is making constant efforts to extend business in the Chinese market. In May, 2012, Eli Lilly and Company China R&D center was formally opened in Shanghai, dedicated to the R&D of diabetes medicines; in June, the Suzhou-based insulin extension project with the investment exceeding USD40 million was also put into service.

Jilin-based Tonghua Dongbao Pharmaceutical is China’s largest recombinant human insulin producer, with the insulin API capacity of 3,000 kg and the insulin preparation capacity of 70 million bottles or 6% market share in China’s recombinant human insulin market. In 2012, the company’s recombinant human insulin injection phase Ⅲ project with the annual capacity of insulin preparation targeting 126 million pcs started construction, and it is expected to be put into production in Q4 2013.

As the world’s fourth and China’s first insulin analog producer, Gan & Lee Pharmaceuticals realized the market share of 6% in China’s insulin analog market in 2011. In April 2012, the insulin phase Ⅲ project of the company held the groundbreaking ceremony. Once the project is put into production as scheduled, the company is expected to increase its capacity of insulin API by 750kg/a and of insulin preparation by 38.5 mln pcs/a.

Enterprises including Hisun Pharmaceutical, United Laboratories and Bayer, with positive outlook of demand for insulin in the Chinese market, are beefing up gaining ground in China through developing new products, building new production bases and agent marketing.

The report highlights the followings:

Global insulin industry: development, supply & demand, product R&D, competition pattern, development trend, etc.
China insulin industry: development, supply & demand, import & export, competition pattern, policy environment, development trend, etc.
Operation, insulin business analysis and development outlook of seven insulin producers worldwide.

1. Insulin Overview
1.1 Definition
1.2 Classification
1.3 Industry Chain

2. Global Insulin Market Development
2.1 Status Quo
2.2 Supply and Demand
2.3 Product R&D
2.4 Competition Pattern
2.5 Development Trend

3. China Insulin Market Development
3.1 Status Quo
3.2 Supply and Demand 
3.3 Export
3.4 Import
3.5 Competition Pattern
3.6 Price
3.7 Policy
3.8 Development Trend

4. Key Insulin Manufacturers
4.1 Novo Nordisk
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 Insulin Business
4.1.7 Business in China
4.1.8 Development Prospect
4.2 Eli Lilly and Company
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Insulin Business
4.2.7 Business in China
4.2.8 Development Prospect
4.3 Sanofi Group
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Insulin Business
4.3.7 Business in China
4.3.8 Development Prospect
4.4 Tonghua Dongbao Pharmaceutical Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Customers
4.4.6 R & D and Investment
4.4.7 Insulin Business
4.4.8 Development Prospect
4.5 Wanbang Biopharmaceuticals 
4.5.1 Profile
4.5.2 Operation
4.6 Gan & Lee Pharmaceuticals
4.6.1 Profile
4.6.2 Operation
4.7 Nanjing Xinbai Pharmaceutical Co. Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Insulin Business

Diabetes Types
Classification of Insulin by Technological Level/Time
Recombiant Human Insulin Production Carrier and Featuers 
Insulin Industy Chain 
World’s Population of Diabetics, 2005-2012 
Population of Diabetics in the World’s Top 10 Countries by Diabetes Developers, 2011 
Market Size of the World’s Top 10 Diabetes Medicines, 2011
Market Scale of Diabetes Medicines Worldwide and YoY Growth Rate, 2004-2011 
Global Diabetics Market Occupancy by Medicine, 2006-2011
Global Insulin Market Scale and YoY Growth Rate, 2005-2011 
Theoretic Demand for Insulin API Worldwide, 2011
Average Per Capita Insulin Consumption Worldwide by Nation, 2000-2010 
R&D Advance of Some Insulin Products Worldwide as of late Jun. 2012 
Global Insulin Pump Market Scale, 2009/2016 
Global Insulin Market Share by Enterprise, 2011 
Global Insulin Production Line and R&D Input Share by Enterprise, 2011 
Population of Diabetics in China, 2007-2011
Market Scale of Diabetes Medicines in China and YoY Growth Rate, 2004-2011
Insulin Medicine Market Share in China, 2006-2011
Market Share of Diabetes Treatment Hospitals in China by Medicine, 2005-2010 
Export Value and Export Price of Insulin and Insulin Salts of China, 2008-2012 
Export Destinations of Insulin and Insulin Salts in China and Proportions, 2011 
Export Value of Insulin-Containing Medicines with Unmeasued Dose in China,2010-2012 
Export Value of Insulin-Containing Medicines with Measued Dose in China by Nation and Proportions, 2011
Export Value of Insulin-Containing Medicines with Measued Dose in China and YoY Growth Rate, 2008-2012
Export Value of Insulin-Containing Medicines with Measued Dose in China by Nation, 2011 
Import Value of Insulin and Insulin Salts and YoY Growth Rate in China, 2008-2011 
Import Value of Insulin and Insulin Salts in China by Country, 2011 
Import Value of Insulin-Containing Medicines with Measued Dose and YoY Growth Rate in China, 2008-2012 
Import Value of Insulin-Containing Medicines with Measued Dose in China by Country, 2011 
Import Value of Insulin Medicines in Representative Hospticals in 22 Cities across China by Variety, 2008-2011
Competitive Enterprises and Market Share in China Insulin Market, 2011 
Competition Pattern of China Recombinant Human Insulin Market, 2011
Competition Pattern of China Insulin Analog Market by Enterprise, 2011 
Ceiling Retail Price of Some Insulin Products in China, 2011 
Insulin Medicines Included in National Health Insurance Directory, 2012 
Key Strategy of Novo Nordisk
Revenue and YoY Growth Rate of Novo Nordisk, 2007-2012
Net Income and YoY Growth Rate of Novo Nordisk, 2007-2012
Revenue of Novo Nordisk by Product, 2007-2012
Revenue of Novo Nordisk by Region, 2007-2012 
Gross Margin of Novo Nordisk, 2007-2012 
R&D Expenditure of Novo Nordisk by Field, 2007-2011
Insulin Market Share of Novo Nordisk by Country, 2011-2012 
Revenue from Insulin Business of Novo Nordisk by Mark, 2009-2012 
Distribution of Subsidaries under Novo Nordisk in China
Revenue and YoY Growth Rate of Novo Nordisk in China, 2007-2012 
Revenue, Net Income and YoY Growth Rate of Novo Nordisk, 2010-2015
Revenue and YoY Growth Rate of Eli Lilly and Company, 2007-2012 
Net Income and YoY Growth Rate of Eli Lilly and Company, 2007-2012 
Revenue of Eli Lilly and Company by Field, 2009-2011
Revenue of Eli Lilly and Company by Region, 2009-2011 
Consolidated Gross Margin of Eli Lilly and Company, 2008-2012 
R&D Expenditure and YoY Growth Rate of Eli Lilly and Company, 2007-2012 
Cooperative Enterperises with Eli Lilly and Company by Product, 2011 
Revenue and YoY Growth Rate from Insulin Business of Eli Lilly and Company by Product, 2008-2012
Revenue from Insulin Business of Eli Lilly and Company by Region, 2008-2012 
Revenue, Net Income and YoY Growth Rate of Eli Lilly and Company, 2010-2015 
Revenue and YoY Growth Rate of Sanofi Group, 2007-2012 
Net Income and YoY Growth Rate of Sanofi Group, 2007-2012 
Revenue of Sanofi Group by Business, 2008-2012
Revenue of Sanofi Group by Region, 2008-2012
Consolidated Gross Margin of Sanofi Group, 2007-2012 
R&D Expenditure of Sanofi Group by Business, 2008-2012 
Revenue and YoY Growth Rate from Insulin Business of Sanofi Group by Product, 2008-2012
Distribution of Subsidaries under Sanofi Group, 2011
Revenue and YoY Growth Rate of Sanofi Group in China, 2009-2012 
Revenue, Net Income and YoY Growth Rate of Sanofi Group, 2010-2015 
Distribution of Subsidaries under Tonghua Dongbao Pharmaceutical, 2011 
Revenue and YoY Growth Rate of Tonghua Dongbao Pharmaceutical, 2007-2012
Net Income and YoY Growth Rate of Tonghua Dongbao Pharmaceutical, 2007-2012 
Revenue of Tonghua Dongbao Pharmaceutical by Product, 2007-2012
Revenue of Tonghua Dongbao Pharmaceutical by Region, 2007-2012 
Gross Margin of Tonghua Dongbao Pharmaceutical by Product, 2007-2012 
Tonghua Dongbao Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2012 
Namelist and Revenue Contribution of Tonghua Dongbao Pharmaceutical’s Top 5 Clients, 2011-2012 
Revenue and YoY Growth Rate from Insulin Business of Tonghua Dongbao Pharmaceutical, 2007-2012 
Revenue, Net Income and YoY Growht Rate of Tonghua Dongbao Pharmaceutical, 2010-2015 
Holding Subsidiaries of Wanbang Biopharmaceuticals
Total Assets and Net Income of Wanbang Biopharmaceuticals, 2009-2011
Insulin Products of Gan & Lee Pharmaceuticals
Revenue and Net Income of Gan & Lee Pharmaceuticals, 2008-2010 
Revenue, Net Income and YoY Growth Rate of Nanjing Xinbai Pharmaceutical, 2007-2011 
Revenue from Insulin Business of Nanjing Xinbai Pharmaceutical, 2008-2011
Gross Profit and Gross Margin from Insulin Business of Nanjing Xinbai Pharmaceutical, 2008-2011

China Diagnostic Reagent Industry Report, 2012-2014

China’s diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in China’s medical care inv...

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号